Last reviewed · How we verify
Ibrutinib, Acalabrutinib, Zanubrutinib
Ibrutinib, Acalabrutinib, Zanubrutinib is a Small molecule drug developed by VA Office of Research and Development. It is currently in Phase 2 development. Also known as: IMBRUVICA, CALQUENCE, BRUKINSA.
At a glance
| Generic name | Ibrutinib, Acalabrutinib, Zanubrutinib |
|---|---|
| Also known as | IMBRUVICA, CALQUENCE, BRUKINSA |
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period (PHASE2)
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma (PHASE3)
- Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (PHASE2)
- A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (PHASE1, PHASE2)
- Mosunetuzumab for CLL MRD Clearance (PHASE1, PHASE2)
- Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy (PHASE2)
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (PHASE2)
- Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ibrutinib, Acalabrutinib, Zanubrutinib CI brief — competitive landscape report
- Ibrutinib, Acalabrutinib, Zanubrutinib updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI
Frequently asked questions about Ibrutinib, Acalabrutinib, Zanubrutinib
What is Ibrutinib, Acalabrutinib, Zanubrutinib?
Ibrutinib, Acalabrutinib, Zanubrutinib is a Small molecule drug developed by VA Office of Research and Development.
Who makes Ibrutinib, Acalabrutinib, Zanubrutinib?
Ibrutinib, Acalabrutinib, Zanubrutinib is developed by VA Office of Research and Development (see full VA Office of Research and Development pipeline at /company/va-office-of-research-and-development).
Is Ibrutinib, Acalabrutinib, Zanubrutinib also known as anything else?
Ibrutinib, Acalabrutinib, Zanubrutinib is also known as IMBRUVICA, CALQUENCE, BRUKINSA.
What development phase is Ibrutinib, Acalabrutinib, Zanubrutinib in?
Ibrutinib, Acalabrutinib, Zanubrutinib is in Phase 2.
Related
- Manufacturer: VA Office of Research and Development — full pipeline
- Also known as: IMBRUVICA, CALQUENCE, BRUKINSA
- Compare: Ibrutinib, Acalabrutinib, Zanubrutinib vs similar drugs
- Pricing: Ibrutinib, Acalabrutinib, Zanubrutinib cost, discount & access